Covid-19 Combined with Stress Cardiomyopathy: Case Report and Review of the Literature

Case Report

Austin Crit Care Case Rep. 2021; 5(3): 1033.

Covid-19 Combined with Stress Cardiomyopathy: Case Report and Review of the Literature

Ren S¹, Li Y², Hao G¹, Long L¹, Shen L¹ and Zhao H¹*

¹Department of Intensive Care Unit, Hebei General Hospital, Hebei, China

²Emergency Department, Cangzhou Central Hospital, Hebei, China

*Corresponding author: Heling Zhao, Department of Intensive Care Unit, Heping West Road, Xinhua Area, Shijiazhuang, Hebei Province, China

Received: September 14, 2021; Accepted: October 08, 2021; Published: October 15, 2021

Abstract

Introduction: Severe COVID-19 can cause multiple organ dysfunction or failure, often associated with cardiac dysfunction, known as stress cardiomyopathy or apical spherical syndrome.

Patient Concerns: Severe COVID-19 patients in Hebei province have 5 cases of stress cardiomyopathy. Two cases in Cangzhou are summarized from Feb 2020 to May 2020.

Diagnosis: Based on the precipitating factor, pathophysiology, Mayo diagnostic criteria and differential diagnosis of stress cardiomyopathy, the patients were diagnosed with stress cardiomyopathy, which is characterized by elevated biomarkers, hemodynamic instability, and cardiomyopathy.

Interventions: Early and dynamic monitoring of ECG, myocardial enzymes, cardiac troponin and echocardiography are needed to predict and assess the risk of stress-induced cardiomyopathy. Noradrenaline and dobutamine were continued to be given, and neokine, levosimendan, Cediland and other drugs were given successively to strengthen the heart.

Outcomes: After several days of supportive care, the patients’s cardiac output and the apical movement were gradually improved.

Conclusion: Reversible stress cardiomyopathy may occur in the setting of COVID-19 infection with elevated cardiac biomarkers and an abnormal ECG and echocardiographic. We should pay more attention to the treatment of stress cardiomyopathy.

Keywords: COVID-19; Takotsubo Cardiomyopathy; Cardiomyopathy; Acute Coronary Syndrome; Novel Coronavirus

Abbreviations

COVID-19: Corona Virus Disease 2019; ECG: Electrocardiogram; ICU: Intensive Care Unit; BNP: B type Natriuretic Peptide; ARDS: Acute Respiratry Distress Syndrome; NT-proBNP: N terminal pro B type Natriuretic Peptide; CK-MB: Isoenzyme of Creatine Kinase; EF: Ejection Fraction; PiCCO: Pulse Indicator Continous Cadiac Output; CO: Cardiac Output; CI: Cardiac Index: Hs-TNT: High Sensitivity Troponin T; ACE2: Angiotensin-Converting Enzyme 2

Introduction

COVID-19 has become a common challenge for all mankind. COVID-19 is classified as light, normal, heavy and severe. According to statistics, COVID-19 incidence accounts for about 20% of the total cases in China, and the mortality rate in Hubei is about 3%. The diagnosis standard of severe COVID-19 is one of the following: 1. Respiratory failure and mechanical ventilation; 2. Shock; 3. ICU monitoring and treatment combination with other organ failure. Severe COVID-19 can cause multiple organ dysfunction or failure, often associated with cardiac dysfunction, known as stress cardiomyopathy or apical spherical syndrome. It is transient left ventricular wall motion abnormalities caused by physical or mental stress factors. Laboratory tests show that myocardial enzymes, muscle calcium protein or BNP increase, and ECG and echocardiographic abnormalities can also occur, such as arrhythmia, left ventricular dysfunction. The decrease of ventricular function can lead to the decrease of cardiac function. When the primary stress factors are controlled, the cardiac function can return to normal. The cardiac function should be closely monitored, and the cardiogenic shock, left ventricular outflow tract obstruction, left ventricular thrombosis and various malignant arrhythmias should be vigilant, such as ventricular fibrillation, atrioventricular block and cardiac arrest [1,2]. Severe COVID-19 patients in Hebei province have 5 cases of stress cardiomyopathy, 2 cases in Cangzhou, including 1 deaths and unknown sources of stress. Two cases of COVID-19 complicated with stress cardiomyopathy in Cangzhou are summarized as follows:

Case Presentation

Case 1

Male, 61 years old, was hospitalized on January 29, 2020, mainly due to fever for 7 days and chest tightness for 4 days. COVID-19 was diagnosed in January 28th. It has history of type 2 diabetes, chronic obstructive pulmonary disease, bronchiectasis, resection of left lung cancer and hypertension. After admission, the patients were given noninvasive ventilator to assist breathing. The oxygenation was poor and circulation was unstable. Dopamine was used to maintain blood pressure at 5μg/kg. Min. severe COVID-19, ARDS, multiple organ dysfunction syndrome (respiratory failure, shock, heart failure) were diagnosed on January 30, blood pressure and heart rate decreased. NT-ProBNP 210pg/ml, CK-MB 18.1U/L, 2-1 NT-ProBNP 35000pg/ ml, CK-MB to 39.5U/L, LDH 775U/L, and myocardial enzymes were all higher than normal range. ECG showed sinus rhythm, low and flat T wave in leads I and AVL, and inverted T wave in leads V2-V6. Echocardiography showed that the left ventricle was enlarged and the range of motion was decreased, especially at the apex of the heart, with EF 37% (Figure 1). In consideration of the existence of stress cardiomyopathy, noradrenaline and dobutamine were continued to be given, and neokine, levosimendan, Cediland and other drugs were given successively to strengthen the heart. The hemodynamic parameters were monitored by PiCCO on February 4, CO 3.27l/min, CI 1.67l/min/m², the cardiac output gradually increased to normal, and the apical movement was improved on February 5. EF was 56% (Figure 2) and apical movement was improved on February 8.

Citation:Ren S, Li Y, Hao G, Long L, Shen L and Zhao H. Covid-19 Combined with Stress Cardiomyopathy: Case Report and Review of the Literature. Austin Crit Care Case Rep. 2021; 5(3): 1033.